Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHEB | Q15382 | 4/20 | 0.61 |
| ▸ | AMY1A | P0DUB6 | 10/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.44 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.42 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.42 |
| ▸ | CFB | P00751 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14514686 | 0.87 | RHEB (0.57) | RHEBMEN1NPC1RAB9AKMT2A | |
| Hydrochloric Acid SCHEMBL5647675 | 0.86 | RHEB (0.56) | RHEBMEN1NPC1RAB9AKMT2A | |
| SCHEMBL5655332 | 0.82 | RHEB (0.67) | RHEBAMY1AMEN1NPC1RAB9A | |
| SCHEMBL10673698 | 0.81 | PDE5A (0.48) | AMY1AMEN1KMT2APKN1PKN2 | |
| SCHEMBL10760601 | 0.80 | MAPK10 (0.42) | RHEBAMY1ANPC1RAB9APKN1 | |
| SCHEMBL11019300 | 0.80 | PKN1 (0.48) | AMY1APKN1PKN2CFB | |
| SCHEMBL10748660 | 0.80 | CDK4 (0.46) | RHEBAMY1APKN1PKN2CFB | |
| SCHEMBL6438041 | 0.78 | KDM4E (0.42) | RHEBMEN1RAB9AKMT2ACFB | |
| SCHEMBL10373620 | 0.77 | PDE3B (0.48) | RHEBAMY1APKN1PKN2CFB | |
| SCHEMBL5650767 | 0.77 | RHEB (0.57) | RHEBAMY1APRSS12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220769-B2 | Azolylbenzamides and analogues and their use for treating osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2007-05-22 | — | — | US | disclosed |
| US-7220769-B2 | Azolylbenzamides and analogues and their use for treating osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2007-05-22 | — | — | US | disclosed |
| US-7220769-B2 | Azolylbenzamides and analogues and their use for treating osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2007-05-22 | — | — | US | disclosed |
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | 3-V BIOSCIENCES, INC. | 2005-02-17 | — | — | US | disclosed |
| EP-1187813-A1 | AZOLYLBENZAMIDES AND ANALOGUES AND THEIR USE FOR TREATING OSTEOPOROSIS | SMITHKLINE BEECHAM PLC (GB) | 2002-03-20 | — | — | EP | disclosed |
| WO-2001000587-A1 | AZOLYLBENZAMIDES AND ANALOGUES AND THEIR USE FOR TREATING OSTEOPOROSIS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | NR0B2, NR0B1, NCOR1 | RHEB 946/4885AMY1A 4499/4885MEN1 3545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.